Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlobalData Plc    DATA   GB00B87ZTG26

GLOBALDATA PLC

(DATA)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

GlobalData : Label update to encourage prescription of anti-diabetic drugs outside the SGLT-2 inhibitor class

share with twitter share with LinkedIn share with facebook
share via e-mail
05/21/2020 | 10:05am EDT
21 May 2020
Label update to encourage prescription of anti-diabetic drugs outside the SGLT-2 inhibitor class
Posted in Pharma

Following the FDA's safety review on sodium glucose-transporter-2 (SGLT-2) inhibitors, a label update was issued stating that patients undergoing any scheduled surgery should discontinue treatment up to 3-4 days in advance of surgery. This label update is expected to influence physician decisions, encouraging the prescription of anti-diabetic drugs outside the SGLT-2 inhibitor class, according to GlobalData, a leading data and analytics company.

Akash Patel, Pharma Analyst at GlobalData, comments: 'Safety issues remain a concern around the profile of SGLT-2 inhibitors, including those identified in the FDA review. SGLT-2 inhibitors can increase the risk of diabetic ketoacidosis (DKA), particularly in the case for patients undergoing surgery. Furthermore, the SGLT-2 inhibitor class of T2D drugs are associated with several side effects that vary between each inhibitor, such as urinary tract infections and genital mycotic infections. These issues will continue to be a threat to the further growth of these drugs' market share within the diabetes space.'

SGLT-2 inhibitors have recently had several label updates for Type 1 Diabetes (T1D), with approvals for Farxiga in the EU and Japan, Suglat in Japan and Zynquista in the EU. In the US, however, similar FDA approval has been challenging with the FDA rejecting applications for both the Farxiga and Zynquista label updates to include T1D patents, with these decisions due in part to the increased risk of DKA in patients taking these treatments.

Akash adds: 'GlobalData expects that the label update will encourage the prescription of anti-diabetic drugs outside the SGLT-2 inhibitor class for some diabetic patients, while the drug class is anticipated to continue facing difficulties gaining FDA approval for treating T1D patients due to their poor safety profile.'

Disclaimer

GlobalData plc published this content on 21 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 May 2020 14:04:05 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GLOBALDATA PLC
06/05GLOBALDATA : France will aid its aerospace industry to preserve its export compe..
AQ
06/05GLOBALDATA : Lasting effects of COVID-19 will force Airbus to take more producti..
AQ
06/05GLOBALDATA : ITC strengthens FMCG portfolio with NimWash Vegetable and Fruit was..
PU
06/04GLOBALDATA : E-commerce sales in Singapore to accelerate further due to COVID-19..
PU
06/04GLOBALDATA : Construction projects schedules are getting delayed due to COVID-19..
PU
06/03GLOBALDATA : reveals top 10 electric vehicles influencers on Twitter in Q1 2020
PU
06/02GLOBALDATA : New ICAO guidelines could keep wide-body aircrafts grounded in post..
AQ
06/02Embraer will need state help to survive COVID-19 crisis, says GlobalData
AQ
06/02GLOBALDATA : As Europe's auto industry re-opens for business, May markets exceed..
PU
06/02GLOBALDATA : ITC and Amway India collaborate to create health halo as COVID-19 c..
PU
More news
Financials
Sales 2020 186 M 236 M 236 M
Net income 2020 23,0 M 29,1 M 29,1 M
Net Debt 2020 35,1 M 44,4 M 44,4 M
P/E ratio 2020 80,6x
Yield 2020 1,17%
Capitalization 1 711 M 2 176 M 2 167 M
EV / Sales 2019
EV / Sales 2020 9,37x
Nbr of Employees 3 355
Free-Float 26,0%
Chart GLOBALDATA PLC
Duration : Period :
GlobalData Plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLOBALDATA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 1 200,00 GBp
Last Close Price 1 450,00 GBp
Spread / Highest target -17,2%
Spread / Average Target -17,2%
Spread / Lowest Target -17,2%
EPS Revisions
Managers
NameTitle
Michael Thomas Danson Chief Executive Officer & Director
Bernard Anthony Cragg Chairman
Graham Charles Lilley Chief Financial Officer, Secretary & Director
Peter Martin Harkness Independent Non-Executive Director
Murray Legg Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
GLOBALDATA PLC12.40%2 176
S&P GLOBAL INC.22.09%80 309
RELX PLC0.21%46 742
THOMSON REUTERS CORPORATION1.43%35 290
EQUIFAX INC.26.01%21 486
WOLTERS KLUWER4.21%20 291